P58 | TRIAL IN PROGRESS: QUINTESSENTIAL-2 – A PHASE 3 STUDY OF ARLOCABTAGENE AUTOLEUCEL VS. STANDARD OF CARE IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA EXPOSED TO LENALIDOMIDE

Introduction. Despite advances in multiple myeloma (MM) treatment, most patients (pts) will relapse, highlighting the need for new drug classes in relapsed/refractory (RRMM). Further, with the extensive use of lenalidomide (LEN), an immunomodulatory drug (IMiD), in frontline and maintenance therapi...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	E. Lebel, A. Abdulgawad, S. Bramanti, G. Garate, P.J. Ho, M. Keränen, Y. Cohen, M. Vase, A. Khot, I. Kristensen, R. Leblanc, C. Lee, W. Legiec, H. Magen, M.V. Mateos, D. Oh, L. Pour, N. Schutz, A. Spyridonidis, K. Weisel, J. Zaucha, S. Larson, A. Varshavsky-Yanovsky, K. Grazioli, D. Basudhar, H. Hu, Y. Meng, L. Eldjerou, S. Bal, S. Harrison, R. Popat, M. Raab, P. Rodriguez-Otero
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Ferrata Storti Foundation 2026-04-01
Ráidu:	Haematologica
Liŋkkat:	https://haematologica.org/article/view/14111
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!